Overview
Small cell carcinoma of the ovary (SCCO), also known as small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), is an extremely rare and aggressive form of ovarian cancer. It most commonly affects young women and adolescents, with the average age at diagnosis being around 24 years old. Despite its name, it is not related to small cell lung cancer. This cancer is now understood to be driven by mutations in a gene called SMARCA4, which normally helps control cell growth. The disease typically presents as a rapidly growing mass in one ovary. One of its hallmark features is high calcium levels in the blood (hypercalcemia), which occurs in about two-thirds of patients and can cause symptoms like excessive thirst, frequent urination, nausea, confusion, and fatigue. Patients often experience abdominal pain, bloating, and a feeling of fullness. The tumor tends to grow quickly and can spread to other parts of the body. Treatment usually involves a combination of surgery to remove the tumor, followed by intensive chemotherapy and sometimes radiation therapy. Because this cancer is so rare and aggressive, there is no single standard treatment protocol that is universally agreed upon. High-dose chemotherapy with stem cell rescue has been used in some cases. Despite treatment, the prognosis has historically been poor, especially for advanced-stage disease, though outcomes are improving with more aggressive multi-modal treatment approaches and emerging targeted therapies. Clinical trials are actively exploring new treatment options, including immune checkpoint inhibitors and drugs targeting the underlying genetic defect.
Also known as:
Key symptoms:
Abdominal pain or pelvic painAbdominal bloating or swellingFeeling full quickly when eatingHigh calcium levels in the bloodExcessive thirstFrequent urinationNausea or vomitingFatigue and weaknessUnexplained weight lossConstipationConfusion or mental fogginess from high calciumA mass or lump felt in the abdomenIrregular menstrual periods
Variable
Can be inherited in different ways depending on the underlying gene
Juvenile
Begins in the teen years
FDA & Trial Timeline
10 eventsConjupro Biotherapeutics, Inc. — PHASE1
Whitehawk Therapeutics, Inc. — PHASE1
European Institute of Oncology — NA
AstraZeneca — PHASE1
Heronova Pharmaceuticals — PHASE1, PHASE2
National Cancer Institute (NCI) — PHASE1
Seagen, a wholly owned subsidiary of Pfizer — PHASE2
Ascendis Pharma Oncology Division A/S — PHASE1, PHASE2
Genmab — PHASE1, PHASE2
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
2 availableTaxol
indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary
Oncoscint CR/OV
For determining the extent and location of extraphepatic malignant disease in patients with known colorectal and ovarian cancer.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Financial Resources
1 resourcesTravel Grants
No travel grants are currently matched to Small cell carcinoma of the ovary.
Community
No community posts yet. Be the first to share your experience with Small cell carcinoma of the ovary.
Start the conversation →Latest news about Small cell carcinoma of the ovary
Disease timeline:
New recruiting trial: A Phase 1 Study of LNCB74 in Advanced Solid Tumors
A new clinical trial is recruiting patients for Small cell carcinoma of the ovary
New recruiting trial: Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
A new clinical trial is recruiting patients for Small cell carcinoma of the ovary
New recruiting trial: Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
A new clinical trial is recruiting patients for Small cell carcinoma of the ovary
New recruiting trial: A Study of DC05F01 in Chinese Patients with Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
A new clinical trial is recruiting patients for Small cell carcinoma of the ovary
New recruiting trial: First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine
A new clinical trial is recruiting patients for Small cell carcinoma of the ovary
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What stage is my cancer, and has it spread beyond the ovary?,Should I have genetic testing for SMARCA4, and what would the results mean for my family?,What are my options for preserving fertility before treatment begins?,What treatment plan do you recommend, and is high-dose chemotherapy with stem cell transplant an option for me?,Are there any clinical trials I should consider, and how do I access them?,Should I be treated at a specialized center with experience in this rare cancer?,What is my expected prognosis, and what follow-up monitoring will I need after treatment?
Common questions about Small cell carcinoma of the ovary
What is Small cell carcinoma of the ovary?
Small cell carcinoma of the ovary (SCCO), also known as small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), is an extremely rare and aggressive form of ovarian cancer. It most commonly affects young women and adolescents, with the average age at diagnosis being around 24 years old. Despite its name, it is not related to small cell lung cancer. This cancer is now understood to be driven by mutations in a gene called SMARCA4, which normally helps control cell growth. The disease typically presents as a rapidly growing mass in one ovary. One of its hallmark features is high calcium l
At what age does Small cell carcinoma of the ovary typically begin?
Typical onset of Small cell carcinoma of the ovary is juvenile. Age of onset can vary across affected individuals.
Are there clinical trials for Small cell carcinoma of the ovary?
Yes — 8 recruiting clinical trials are currently listed for Small cell carcinoma of the ovary on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Small cell carcinoma of the ovary?
23 specialists and care centers treating Small cell carcinoma of the ovary are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.
What treatment and support options exist for Small cell carcinoma of the ovary?
2 patient support programs are currently tracked on UniteRare for Small cell carcinoma of the ovary. See the treatments and support programs sections for copay assistance, eligibility, and contact details.